Cargando…
Concepts in Oncolytic Adenovirus Therapy
Oncolytic adenovirus therapy is gaining importance as a novel treatment option for the management of various cancers. Different concepts of modification within the adenovirus vector have been identified that define the mode of action against and the interaction with the tumour. Adenoviral vectors al...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508870/ https://www.ncbi.nlm.nih.gov/pubmed/34638863 http://dx.doi.org/10.3390/ijms221910522 |
_version_ | 1784582200284413952 |
---|---|
author | Mantwill, Klaus Klein, Florian Gerhard Wang, Dongbiao Hindupur, Sruthi Vasantamadhava Ehrenfeld, Maximilian Holm, Per Sonne Nawroth, Roman |
author_facet | Mantwill, Klaus Klein, Florian Gerhard Wang, Dongbiao Hindupur, Sruthi Vasantamadhava Ehrenfeld, Maximilian Holm, Per Sonne Nawroth, Roman |
author_sort | Mantwill, Klaus |
collection | PubMed |
description | Oncolytic adenovirus therapy is gaining importance as a novel treatment option for the management of various cancers. Different concepts of modification within the adenovirus vector have been identified that define the mode of action against and the interaction with the tumour. Adenoviral vectors allow for genetic manipulations that restrict tumour specificity and also the expression of specific transgenes in order to support the anti-tumour effect. Additionally, replication of the virus and reinfection of neighbouring tumour cells amplify the therapeutic effect. Another important aspect in oncolytic adenovirus therapy is the virus induced cell death which is a process that activates the immune system against the tumour. This review describes which elements in adenovirus vectors have been identified for modification not only to utilize oncolytic adenovirus vectors into conditionally replicating adenoviruses (CRAds) that allow replication specifically in tumour cells but also to confer specific characteristics to these viruses. These advances in development resulted in clinical trials that are summarized based on the conceptual design. |
format | Online Article Text |
id | pubmed-8508870 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85088702021-10-13 Concepts in Oncolytic Adenovirus Therapy Mantwill, Klaus Klein, Florian Gerhard Wang, Dongbiao Hindupur, Sruthi Vasantamadhava Ehrenfeld, Maximilian Holm, Per Sonne Nawroth, Roman Int J Mol Sci Review Oncolytic adenovirus therapy is gaining importance as a novel treatment option for the management of various cancers. Different concepts of modification within the adenovirus vector have been identified that define the mode of action against and the interaction with the tumour. Adenoviral vectors allow for genetic manipulations that restrict tumour specificity and also the expression of specific transgenes in order to support the anti-tumour effect. Additionally, replication of the virus and reinfection of neighbouring tumour cells amplify the therapeutic effect. Another important aspect in oncolytic adenovirus therapy is the virus induced cell death which is a process that activates the immune system against the tumour. This review describes which elements in adenovirus vectors have been identified for modification not only to utilize oncolytic adenovirus vectors into conditionally replicating adenoviruses (CRAds) that allow replication specifically in tumour cells but also to confer specific characteristics to these viruses. These advances in development resulted in clinical trials that are summarized based on the conceptual design. MDPI 2021-09-29 /pmc/articles/PMC8508870/ /pubmed/34638863 http://dx.doi.org/10.3390/ijms221910522 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Mantwill, Klaus Klein, Florian Gerhard Wang, Dongbiao Hindupur, Sruthi Vasantamadhava Ehrenfeld, Maximilian Holm, Per Sonne Nawroth, Roman Concepts in Oncolytic Adenovirus Therapy |
title | Concepts in Oncolytic Adenovirus Therapy |
title_full | Concepts in Oncolytic Adenovirus Therapy |
title_fullStr | Concepts in Oncolytic Adenovirus Therapy |
title_full_unstemmed | Concepts in Oncolytic Adenovirus Therapy |
title_short | Concepts in Oncolytic Adenovirus Therapy |
title_sort | concepts in oncolytic adenovirus therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508870/ https://www.ncbi.nlm.nih.gov/pubmed/34638863 http://dx.doi.org/10.3390/ijms221910522 |
work_keys_str_mv | AT mantwillklaus conceptsinoncolyticadenovirustherapy AT kleinfloriangerhard conceptsinoncolyticadenovirustherapy AT wangdongbiao conceptsinoncolyticadenovirustherapy AT hindupursruthivasantamadhava conceptsinoncolyticadenovirustherapy AT ehrenfeldmaximilian conceptsinoncolyticadenovirustherapy AT holmpersonne conceptsinoncolyticadenovirustherapy AT nawrothroman conceptsinoncolyticadenovirustherapy |